Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC) - Olorinab initiation of the Phase 2 CAPTIVATE clinical trial in abdominal pain associated with irritable bowel syndrome (IBS) - Multiple first- or best-in-class drug candidates, skilled leadership team and
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
SAN DIEGO , July 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results
- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis - Multiple first- or best-in-class therapeutics, strong leadership team and liquidity position of approximately $1.3 billion SAN DIEGO , May 8, 2019 /PRNewswire/ -- Arena
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8
SAN DIEGO , May 1, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
- Etrasimod demonstrated clinical response and durable, long-term clinical remission and favorable long-term safety and tolerability in an open-label extension trial - Completed global license agreement with United Therapeutics for ralinepag, received $800M upfront payment, and eligible to receive
View HTML
Toggle Summary Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26
SAN DIEGO , Feb. 20, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live webcast to
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results
- Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD - Olorinab positive Phase 2a data for the treatment of pain associated with Crohn's disease; all patients with evaluable data at week 8 exhibited a pre-defined clinical improvement SAN DIEGO ,
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
SAN DIEGO , Oct. 31, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its third quarter 2018 financial results and provide a corporate update on Wednesday, November 7, 2018 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2018 Financial Results
- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH) - Completed Enrollment for Olorinab Study for Pain Associated with Crohn's Disease; Data in Q3:18 - Submitted Etrasimod Meeting Request to the FDA for Ulcerative Colitis (UC) SAN DIEGO , Aug.
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6
SAN DIEGO , July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018 , after the close of the U.S.
View HTML